fbpx

molecules of the month

repotrectinib

oral, CNS-penetrant TRK(A-C) kinase inhibitor

Ph. II candidate for solid tumors (160 mg QD)

from literature starting point

Molecular Cancer Therapeutics

Turning Point Therapeutics, San Diego, CA

Chemical structure of molecule repotrectinib (TPX-0005)
1 min read

The Turning Point Therapeutics oral, brain-penetrant ALK/ROS1/TRK kinase inhibitor, repotrectinib (TPX-0005), is a macrocyclic molecule with a small size intended to limit adverse interactions with resistance mutation hotspots near kinase active sites. TRK fusion proteins are driver mutations in certain cancers (which respond well to larotrectinib and entrectinib) but resistance is anticipated to be a problem. This molecule inhibits TRKA, TRKB, TRC, ROS1, and various forms of ALK, and durable responses were observed in both TKI-naïve and pretreated patients with NTRK+ cancers (NCT03093116).


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: